CD44 and neoplasm: Whilst the ER status of BCSCs enriched in ER + ve tumor cells resistant to endocrine therapy is not clear, evidence suggests the ER-ve status of both CD44+CD24−/low and ALDH1+ BCSCs [76,137,138].